Trials
16 active
31 in total · 19 in the EU
What this is
- How it works
- BAFF receptor (BAFF-R) antibody
- How it’s given
- “VAY736 once monthly solution for injection for subcutaneous use.”In the company’s words, NCT07621809 on ClinicalTrials.gov
- Tested for
- Primary Immune Thrombocytopenia (ITP) (4 trials), Systemic Lupus Erythematosus (4 trials), Lupus Nephritis (2 trials), Sjogren Syndrome, Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia (wAIHA), Sjögren´s Disease, Sjogrens Syndrome and 4 more
- Main trialPhase 3
- “A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)”In the company’s words, NCT05349214 on ClinicalTrials.gov
- Other names
- VAY736
Other drugs for Primary Immune Thrombocytopenia (ITP)
- RilzabrutinibSanofi · Phase 3
- Human immunoglobulinGrand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- TQB3473Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Efgartigimodargenx · Phase 3
- QL0911Qilu Pharmaceutical · Phase 3
Coming up10
- 26 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- 12 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 21 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 18 Jan 2029Phase 2 trial completes · ClinicalTrials.gov
- 15 Aug 2029Phase 3 trial completes · ClinicalTrials.gov
- 22 Apr 2033Phase 3 trial completes · ClinicalTrials.gov
- 22 Apr 2033Phase 2 trial completes · ClinicalTrials.gov
- 3 Apr 2034Phase 3 trial completes · ClinicalTrials.gov
- 1 Aug 2035Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials31
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 13 May 2025 | Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome | |
| Phase 3Active, not recruiting | 19 Jun 2025 | A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids | |
| Phase 3Active, not recruiting | 20 Feb 2026 | A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia | |
| Phase 3Active, not recruiting | 29 Oct 2026 | Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) | |
| Phase 3Active, not recruiting | 26 Mar 2027 | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | |
| Phase 3Active, not recruiting | 12 Apr 2027 | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | |
| Phase 3Active, not recruiting | 21 Sep 2027 | Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | |
| Phase 3Recruiting | 15 Aug 2029 | Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden | |
| Phase 3Active, not recruiting | 22 Apr 2033 | A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. | |
| Phase 3Recruiting | 3 Apr 2034 | Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | |
| Phase 3Recruiting | 1 Aug 2035 | Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) | |
| Phase 2Active, not recruiting | 5 Feb 2025 | A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies | |
| Phase 2Active, not recruiting | 17 Feb 2026 | Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | |
| Phase 2Active, not recruiting | 30 Jul 2027 | A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | |
| Phase 2Recruiting | 18 Jan 2029 | A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) | |
| Phase 2Not yet recruiting | 22 Apr 2033 | A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. | |
| Phase 3Completed | 7 May 2025 | Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome | |
| Phase 2/3Completed | 28 Dec 2023 | ADCC Mediated B-Cell dEpletion and BAFF-R Blockade | |
| Phase 2Terminated | 5 May 2015 | A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis | |
| Phase 2Completed | 7 Feb 2018 | PD of VAY736 in Patients With Primary Sjögren's Syndrome | |
| Phase 2Terminated | 25 Sep 2019 | Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris | |
| Phase 2Completed | 30 Jun 2020 | Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS) | |
| Phase 2Terminated | 25 Nov 2020 | Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis | |
| Phase 2Completed | 27 Jul 2022 | Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients | |
| Phase 2Completed | 26 Jun 2024 | Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments. | |
| Phase 2Completed | 4 Dec 2024 | Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 2Withdrawn | 30 Aug 2030 | Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab | |
| Phase 1Terminated | 29 Sep 2023 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | |
| Phase 1Completed | 18 Jul 2024 | Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis | |
| Phase 1Terminated | 24 Feb 2025 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | |
| Phase 1Withdrawn | 17 Dec 2025 | Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026